rss
Evid Based Med 18:179 doi:10.1136/eb-2012-101100
  • Therapeutics
  • Randomised controlled trial

Tiotropium bromide triple combination therapy improves lung function and decreases asthma exacerbations

  1. Stephen P Peters
  1. Wake Forest School of Medicine, Center for Genomics, Medical Center Boulevard, Winston-Salem, North Carolina, USA
  1. Correspondence to : Professor Stephen P Peters
    Wake Forest School of Medicine, Center for Genomics, Medical Center Boulevard, Winston-Salem, NC 27157, USA; sppeters{at}wakehealth.edu

Commentary on:

Context

Three recent well-designed clinical trials demonstrated that tiotropium bromide, when added to an inhaled corticosteroid (ICS), provides asthma control which is non-inferior to adding a long-acting β-agonist (LABA).13 The third of these trials also suggested that adding tiotropium to an ICS–LABA combination also provides additional benefit, as measured by an improvement in lung function (FEV1).3 Whether adding tiotropium to patients inadequately controlled on combination ICS–LABA therapy would provide additional benefit by improving long-term asthma control and decreasing severe asthma exacerbations was the subject of …

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBM.
View free sample issue >>


Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article